Agonism, Antagonism, and Partial Agonism

Drugs that bind the same receptor can act in opposite ways. An agonist activates the receptor and produces a response; an antagonist binds without activating it and blocks the action of agonists; a partial agonist activates the receptor but can only produce a submaximal response even at full occupancy. These categories, together with inverse agonism, classify drugs by what their binding does to receptor activity.

Definition

An agonist binds and activates a receptor to produce a response; an antagonist binds without activating and reduces the effect of agonists; a partial agonist binds and activates the receptor but yields only a submaximal maximal effect; an inverse agonist reduces constitutive (agonist-independent) receptor activity below baseline.

Scope

This topic defines full, partial, and inverse agonism and competitive and non-competitive antagonism, explains the molecular basis of each in terms of affinity and efficacy, and outlines how they appear on dose-response curves. It is a reference and educational entry and does not recommend specific agents or treatments.

Core questions

• What distinguishes an agonist, an antagonist, and a partial agonist at the molecular level?
• How do competitive and non-competitive (and reversible versus irreversible) antagonism differ?
• Why can a partial agonist act as an antagonist in the presence of a full agonist?
• What is an inverse agonist, and what does it imply about constitutive receptor activity?

Key concepts

• Full agonist
• Partial agonist
• Antagonist (competitive and non-competitive)
• Reversible versus irreversible antagonism
• Inverse agonist and constitutive activity
• Surmountable versus insurmountable blockade
• Biased agonism (functional selectivity)
• Schild analysis

Key theories

Two-state (and extended) receptor models

Receptors are modelled as existing in equilibrium between inactive and active conformations; agonists preferentially bind and stabilise the active state, antagonists bind without shifting the equilibrium, partial agonists shift it incompletely, and inverse agonists stabilise the inactive state, accounting for the full spectrum of ligand efficacy including effects on constitutive activity.

Operational classification of agonism

Black and Leff's operational model expresses agonist behaviour through affinity and a transducer (efficacy) term, so that full agonism, partial agonism, and antagonism emerge as a continuum of efficacy values rather than rigidly separate categories.

Mechanisms

Ligands at a receptor differ in efficacy. A full agonist has high efficacy and stabilises the active receptor conformation, producing the maximal tissue response; a partial agonist has intermediate efficacy and cannot produce the maximal response even at full occupancy, so in the presence of a full agonist it lowers the overall effect and behaves as a partial antagonist. A competitive antagonist binds reversibly at the same site, has zero efficacy, and shifts the agonist concentration-response curve to the right in a surmountable way (the basis of Schild analysis); a non-competitive or irreversible antagonist depresses the maximal response. An inverse agonist reduces receptor activity below the constitutive baseline. The recognition of biased agonism, in which a ligand activates some downstream pathways (for example G-protein versus arrestin signalling) more than others, refined the simple agonist-antagonist dichotomy. Standardised definitions of these terms are maintained by international pharmacology nomenclature.

Clinical relevance

Classifying a drug as an agonist, antagonist, partial agonist, or inverse agonist describes how it will modify the activity of its target relative to the endogenous signalling - for instance whether it mimics, blocks, or partially substitutes for a natural mediator. This entry is conceptual and educational and does not provide guidance on selecting or dosing such drugs.

Evidence & guidelines

The IUPHAR Committee on Receptor Nomenclature and Drug Classification defines agonist, partial agonist, inverse agonist, and antagonist and the symbols used in antagonist potency analysis (such as pA2), providing the standardised terminology for classifying drug action at receptors.

History

Ariens (intrinsic activity) and Stephenson (efficacy) in the 1950s provided the conceptual basis for distinguishing full from partial agonists and from antagonists. Schild developed the quantitative analysis of competitive antagonism, and Black's work on receptor antagonists demonstrated the therapeutic importance of selective blockade. The later discovery of constitutive receptor activity introduced inverse agonism, and studies of arrestin-dependent signalling by Lefkowitz and colleagues established biased agonism as a further refinement of the classification.

Debates

How real and useful is biased agonism?

Ligands can preferentially engage some downstream pathways over others at the same receptor, suggesting a route to separating desired from undesired effects, but quantifying bias robustly and translating it into predictable outcomes remains methodologically contested.

Key figures

• Robert Stephenson
• Everardus Ariens
• James Black
• Heinz Otto Schild
• Robert Lefkowitz

Seminal works

• black-leff-1983
• stephenson-1956
• lefkowitz-2005

Frequently asked questions

How can a partial agonist also act as an antagonist?

Because it occupies receptors but produces only a submaximal effect, a partial agonist competes with a full agonist for the same sites; in the presence of the full agonist it lowers the overall response, so it behaves functionally as an antagonist while still producing some effect on its own.

What is an inverse agonist?

An inverse agonist binds a receptor that has some baseline (constitutive) activity and reduces that activity below its resting level, producing an effect opposite in direction to an agonist rather than simply blocking agonist action.